EMERYVILLE, Calif., Oct. 24, 2016-- Adamas Pharmaceuticals, Inc. today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, will present at the Credit Suisse Healthcare ...
- Capital Cube•12 days agoAdamas Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ADMS-US : October 13, 2016
Categories: ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Adamas Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more (Read more...)
- Zacks•last month
Allergan plc (AGN) and Adamas Pharmaceuticals, Inc. (ADMS) announced that four new dosage strengths for the new expanded indication of its Alzheimer's drug, Namzaric XR capsules, are now available in the U.S.
Adamas Pharmaceuticals, Inc. (ADMS)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
|Bid||13.38 x 100|
|Ask||15.11 x 200|
|Day's Range||14.47 - 14.79|
|52wk Range||12.02 - 31.84|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-5.15|
|Avg Vol (3m)||225,813|
|Dividend & Yield||N/A (N/A)|